Double Carbapenem as Rescue Strategy for the Treatment of Carbapenemase-Producing Klebsiella Pneumoniae Infections

An observational two-center case-control study exploring the clinical impact of double-carbapenem use in a population of critically il patients with severe carbapenem-resistant Klebsiella pneumoniae infection

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Carbapenem Klebsiella Pneumonia

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

age ≥ 18 years;
ICU admission between November 2012 and December 2015;
documented CR-Kp invasive infection;
targeted antibiotic therapy lasting ≥ 72 hours

Exclusion criteria

Klebsiella infection, susceptible to carbapenems
Duration of antimicrobial therapy less than 72 hours
Data not completely available from the electronically medical chart

Treatment and study plan

None intervention

Other

none intervention

Primary outcomes

28-day mortality

Time frame: 28 day

mortality after 28 day from infection

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other

Registry information

Official study title

Double Carbapenem as Rescue Strategy for the Treatment of Severe Carbapenemase-Producing Klebsiella Pneumoniae Infections: A Two-Center Matched Case-Control Study

Important dates

Study start: 2012
Primary completion: 2015
Study completion: 2016
First posted: Mar 29, 2017
Registry last updated: Mar 29, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed